{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:04:19Z","timestamp":1790633059845,"version":"4.1.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The ongoing spread of antimicrobial resistance has made the treatment of uncomplicated urinary tract infections (UTIs) and urogenital gonorrhoea increasingly difficult. New oral treatment options are urgently needed. Gepotidacin (previously GSK2140944) is a novel, bactericidal, oral, \u2018first-in-class\u2019 triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking two essential topoisomerase enzymes. Mutations in both enzymes would likely be necessary for resistance to occur, thus raising hopes that the drug will be able to maintain long-term effectiveness. Data from Phase II clinical trials of gepotidacin in UTIs and urogenital gonorrhoea appear promising, and Phase III trials are underway. In this review we summarize the development of gepotidacin and discuss its potential role in clinical practice. If approved, gepotidacin will be the first new oral antibiotic for UTIs in more than 20 years.<\/jats:p>","DOI":"10.1093\/jac\/dkad060","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T08:29:46Z","timestamp":1677227386000},"page":"1137-1142","source":"Crossref","is-referenced-by-count":47,"title":["Gepotidacin: a novel, oral, \u2018first-in-class\u2019 triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea"],"prefix":"10.1093","volume":"78","author":[{"given":"Richard R","family":"Watkins","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Northeast Ohio Medical University , Rootstown, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipendra","family":"Thapaliya","sequence":"additional","affiliation":[{"name":"Department of Medicine, MetroHealth Medical Center , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L","family":"Lemonovich","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, MetroHealth Medical Center , Cleveland, OH , USA"},{"name":"Case Western Reserve University School of Medicine , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3299-894X","authenticated-orcid":false,"given":"Robert A","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine , Cleveland, OH , USA"},{"name":"Case Western Reserve University-Cleveland VA Medical Center for Antimicrobial Resistance and Epidemiology (Case VA CARES) , Cleveland, OH , USA"},{"name":"Research Service, VA Northeast Ohio Healthcare System , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"2023050300193142600_dkad060-B1","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","author":"GBD 2019 Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2023050300193142600_dkad060-B2","article-title":"An introduction to the epidemiology and burden of urinary tract infections","volume":"11","author":"Medina","journal-title":"Ther Adv Urol"},{"key":"2023050300193142600_dkad060-B3","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023050300193142600_dkad060-B4","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw159","article-title":"Outpatient antibiotic prescribing practices for uncomplicated urinary tract infection in women in the United States, 2002\u20132011","volume":"3","author":"Kobayashi","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2023050300193142600_dkad060-B5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s15010-014-0659-4","article-title":"Beyond antibiotic selection: concordance with the IDSA guidelines for uncomplicated urinary tract infections","volume":"43","author":"Kim","year":"2015","journal-title":"Infection"},{"key":"2023050300193142600_dkad060-B6","article-title":"Long-term impact of fluoroquinolone-sparing strategies for empirical treatment of acute uncomplicated cystitis among ambulatory patients","volume":"9","author":"Kon","year":"2022","journal-title":"Ther Adv Infect Dis"},{"key":"2023050300193142600_dkad060-B7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.idc.2020.04.002","article-title":"Overview: the ongoing threat of antimicrobial resistance","volume":"34","author":"Watkins","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"2023050300193142600_dkad060-B8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.pop.2018.05.005","article-title":"Urinary tract infection antibiotic resistance in the United States","volume":"45","author":"Waller","year":"2018","journal-title":"Prim Care"},{"key":"2023050300193142600_dkad060-B9","doi-asserted-by":"crossref","first-page":"iii25","DOI":"10.1093\/jac\/dkq298","article-title":"Complicated urinary tract infections: practical solutions for the treatment of multiresistant gram-negative bacteria","volume":"65","author":"Pallett","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2023050300193142600_dkad060-B10","doi-asserted-by":"crossref","first-page":"10048","DOI":"10.1038\/s41598-022-14177-y","article-title":"The impact of the ST131 clone on recurrent ESBL-producing E. coli urinary tract infection: a prospective comparative study","volume":"12","author":"Lindblom","year":"2022","journal-title":"Sci Rep"},{"key":"2023050300193142600_dkad060-B11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ajem.2021.06.044","article-title":"The prevalence and predictors of extended spectrum B-lactamase urinary tract infections among emergency department patients: a retrospective chart review","volume":"49","author":"Chebl R","year":"2021","journal-title":"Am J Emerg Med"},{"key":"2023050300193142600_dkad060-B12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/14728214.2017.1293650","article-title":"An update on emerging therapies for urinary tract infections","volume":"22","author":"Majeed","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"key":"2023050300193142600_dkad060-B13","author":"Centers for Disease Control and Prevention"},{"key":"2023050300193142600_dkad060-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"2023050300193142600_dkad060-B15","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.46.2200803","article-title":"Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022","volume":"27","author":"Day","year":"2022","journal-title":"Euro Surveill"},{"key":"2023050300193142600_dkad060-B16","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01570-22","article-title":"Emergence and genomic characterization of Neisseria gonorrhoeae isolates with high levels of ceftriaxone and azithromycin resistance in Guangdong, China, from 2016 to 2019","volume":"10","author":"Lin","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2023050300193142600_dkad060-B17","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3390\/genes13081397","article-title":"Molecular factors and mechanisms driving multidrug resistance in uropathogenic Escherichia coli\u2013an update","volume":"13","author":"Rozwadowski","year":"2022","journal-title":"Genes (Basel)"},{"key":"2023050300193142600_dkad060-B18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"2023050300193142600_dkad060-B19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01263-21","article-title":"Pharmacokinetics of oral formulations of gepotidacin (GSK2140944), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, in healthy adult and adolescent participants","volume":"66","author":"Barth","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B20","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlac066","article-title":"Antibiotic stewardship in the era of precision medicine","volume":"4","author":"Watkins","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2023050300193142600_dkad060-B21","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1016\/j.jmb.2019.07.008","article-title":"DNA topoisomerase inhibitors: trapping a DNA-cleaving machine in motion","volume":"431","author":"Bax","year":"2019","journal-title":"J Mol Biol"},{"key":"2023050300193142600_dkad060-B22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2147\/JEP.S259286","article-title":"Investigational and experimental drugs for community-acquired pneumonia: the current evidence","volume":"12","author":"Sellar\u00e8s-Nadal","year":"2020","journal-title":"J Exp Pharmacol"},{"key":"2023050300193142600_dkad060-B23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02047-16","article-title":"In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae","volume":"61","author":"Farrell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect Dis"},{"key":"2023050300193142600_dkad060-B25","article-title":"In vitro activity of GSK2140944, a novel topoisomerase inhibitor, against isolates associated with lower respiratory tract and skin infections","author":"Bouchillon"},{"key":"2023050300193142600_dkad060-B26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00207-19","article-title":"Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations","volume":"63","author":"Szili","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it\u2019s not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2023050300193142600_dkad060-B28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00122-21","article-title":"Gepotidacin pharmacokinetics-pharmacodynamics against Escherichia coli in the one-compartment and hollow-fiber in vitro infection model systems","volume":"65","author":"VanScoy","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023050300193142600_dkad060-B30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00199-20","article-title":"Phase 2a pharmacokinetic, safety, and exploratory efficacy evaluation of oral gepotidacin (GSK2140944) in female participants with uncomplicated urinary tract infection (acute uncomplicated cystitis)","volume":"64","author":"Overcash","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/00498254.2015.1112933","article-title":"The metabolism and disposition of GSK2140944 in healthy human subjects","volume":"46","author":"Negash","year":"2016","journal-title":"Xenobiotica"},{"key":"2023050300193142600_dkad060-B32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B33","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02820-15","article-title":"In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/jac\/dkac406","article-title":"In vitro activity of gepotidacin against urine isolates of Escherichia coli from outpatient departments in Germany","volume":"78","author":"Kresken","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2023050300193142600_dkad060-B35","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2021.115484","article-title":"Analysis of antimicrobial susceptibility testing methods and variables and in vitro activity of gepotidacin against urogenital Neisseria gonorrhoeae in men","volume":"101","author":"Scangarella-Oman","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023050300193142600_dkad060-B36","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2023050300193142600_dkad060-B37","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02165-21","article-title":"In vitro activity of gepotidacin against Gram-negative and Gram-positive anaerobes","volume":"66","author":"Hackel","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12866-021-02245-8","article-title":"Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)","volume":"21","author":"Nuzzo","year":"2021","journal-title":"BMC Microbiol"},{"key":"2023050300193142600_dkad060-B39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02385-16","article-title":"A phase I, randomized, double-blinded, placebo- and moxifloxacin-controlled, four-period crossover study to evaluate the effect of gepotidacin on cardiac conduction as assessed by 12-lead electrocardiogram in healthy volunteers","volume":"61","author":"Hossain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B40","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/cpdd.913","article-title":"Pharmacokinetics of gepotidacin in subjects with normal hepatic function and hepatic impairment","volume":"10","author":"Hossain","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2023050300193142600_dkad060-B41","article-title":"Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed Gram-positive acute bacterial skin and skin structure infections","volume":"61","author":"O\u2019Riordan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B42","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01302-19","article-title":"In vitro activity and microbiological efficacy of gepotidacin from a phase 2, randomized, multicenter, dose-ranging study in patients with acute bacterial skin and skin structure infections","volume":"64","author":"Scangarella-Oman","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B43","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s40121-022-00706-9","article-title":"Design of two phase III, randomized, multicenter studies comparing gepotidacin with nitrofurantoin for the treatment of uncomplicated urinary tract infection in female participants","volume":"11","author":"Perry","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2023050300193142600_dkad060-B44","author":"Kaltwasser"},{"key":"2023050300193142600_dkad060-B45","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/cpdd.1192","article-title":"Pharmacokinetic, safety, and tolerability evaluations of gepotidacin (GSK2140944) in healthy Japanese participants","volume":"12","author":"Barth","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2023050300193142600_dkad060-B46","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00086-19","article-title":"Efficacy of human exposures of gepotidacin (GSK2140944) against Escherichia coli in a rat pyelonephritis model","volume":"63","author":"Hoover","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/sextrans-2022-055518","article-title":"Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea","volume":"99","author":"Scangarella-Oman","year":"2022","journal-title":"Sex Transm Infect"},{"key":"2023050300193142600_dkad060-B48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg1787","article-title":"Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague","volume":"14","author":"Jakielaszek","year":"2022","journal-title":"Sci Transl Med"},{"key":"2023050300193142600_dkad060-B49","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01064-17","article-title":"In vitro activities of gepotidacin (GSK2140944) and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"61","author":"Waites","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B50","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1080\/22221751.2020.1775498","article-title":"In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium","volume":"9","author":"Jensen","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2023050300193142600_dkad060-B51","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00564-22","article-title":"In vitro and in vivo activity of gepotidacin against drug-resistant mycobacterial infections","volume":"66","author":"Ahmad","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300193142600_dkad060-B52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/acsmedchemlett.1c00549","article-title":"Structure-activity relationship of anti- Mycobacterium abscessus piperidine-4-carboxamides, a new class of NBTI DNA gyrase inhibitors","volume":"13","author":"Beuchel","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"2023050300193142600_dkad060-B53","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/antibiotics11020192","article-title":"Antibacterial activity of the novel drug gepotidacin against Stenotrophomonas maltophilia\u2013an in vitro and in vivo study","volume":"11","author":"Sanders","year":"2022","journal-title":"Antibiotics (Basel)"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/5\/1137\/50148978\/dkad060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/5\/1137\/50148978\/dkad060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T20:20:34Z","timestamp":1683058834000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/5\/1137\/7072215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3,8]]},"published-print":{"date-parts":[[2023,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad060","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,3]]},"published":{"date-parts":[[2023,3,8]]}}}